PubAg

Main content area

Dual genetic absence of STAT6 and IL-10 does not abrogate anti-hyperglycemic effects of Schistosoma mansoni in streptozotocin-treated diabetic mice

Author:
Osada, Yoshio, Fujiyama, Tomohiro, Kamimura, Naoto, Kaji, Tsukushi, Nakae, Susumu, Sudo, Katsuko, Ishiwata, Kenji, Kanazawa, Tamotsu
Source:
Experimental parasitology 2017 v.177 pp. 1-12
ISSN:
0014-4894
Subject:
Schistosoma mansoni, animal disease models, glycemic effect, hyperglycemia, insulin-dependent diabetes mellitus, interleukin-10, islets of Langerhans, lymph nodes, macrophages, mice, parasites, protective effect, spleen, streptozotocin
Abstract:
Schistosoma mansoni (Sm) is known to exert protective effects against various allergic and autoimmune disorders. It has been reported that this parasite protects NOD mice from spontaneous type 1 diabetes (T1D) and ameliorates streptozotocin (STZ)-induced T1D in wild-type mice. Here, we tried to clarify the anti-diabetic mechanisms of Sm in the latter model. Sm infection partially prevented the degradation of pancreatic islets and hyperglycemia in multiple low-dose (MLD) STZ-treated mice. Neither Treg cell depletion nor genetic absences of IL-10 and/or STAT6 abrogated the anti-hyperglycemic effects of Sm. Among M2 macrophage markers, Arg-1 and Ym1, but not Retnla, remained up-regulated in the pancreatic lymph nodes and in the spleens of STAT6/IL-10 double deficient (DKO) mice. Collectively, it is suggested that Sm exerts anti-diabetic effects on this experimental T1D model via Treg/IL-4/IL-13/IL-10-independent mechanisms. Augmented expressions of Arg-1 and Ym1 in the lymphoid organs adjacent to pancreas may be relevant to the anti-diabetic effects of Sm.
Agid:
5660111